Compare CMRC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMRC | OABI |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | 1079 | 89 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.3M | 237.4M |
| IPO Year | N/A | N/A |
| Metric | CMRC | OABI |
|---|---|---|
| Price | $2.92 | $1.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $4.88 | $4.50 |
| AVG Volume (30 Days) | ★ 587.8K | 555.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.11 | $52.42 |
| Revenue Next Year | $4.50 | $64.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $1.22 |
| 52 Week High | $5.55 | $2.22 |
| Indicator | CMRC | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 38.93 |
| Support Level | $2.43 | $1.32 |
| Resistance Level | $3.10 | $1.70 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 63.95 | 4.55 |
Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.